NCT07160946招募中不适用
Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 6,000 人开始时间: 2025年5月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 6,000
- 试验地点
- 1
- 主要终点
- Number and specific time of participants progressing to liver cancer
研究概览
简要总结
Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •must meet (a) and any one of (b) to (g).
- •(a).Positive for Hepatitis B surface antigen; (b).Ultrasound/CT/MR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis/ liver cancer; (e). Long term alcohol consumption history (>5 years), equivalent to alcohol consumption of ≥ 40g/d for males and ≥ 20g/d for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.
排除标准
- •(a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time<1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.
结局指标
主要结局
Number and specific time of participants progressing to liver cancer
时间窗: 5 years
Number and specific time of participants progressing to liver cancer
次要结局
- Survival time(5 years)
研究者
Lin Bingliang
Prof.
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver CancerHepatocellular CarcinomaNCT05371873First Affiliated Hospital of Zhejiang University250
招募中
2 期
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaHepatocellular CarcinomaNCT06904170UNICANCER196
尚未招募
不适用
Liver Cancer data collection in Indian population .Liver cell carcinoma,CTRI/2019/12/022387Asian Institute of Gastroenterology500
招募中
1 期
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma PatientsHepatocellular CarcinomaNCT05281926National Taiwan University Hospital10
已完成
3 期
Screening of Hepatocellular Carcinoma in Patients With Compensated CirrhosisCompensated CirrhosisNCT00190385Assistance Publique - Hôpitaux de Paris1,200